Sangrix restates interim financials after correcting share classification and warrant dividend errors

Sangrix filed a Form 6-K/A restating interim financial statements for the six months ended Dec. 31, 2025. Restatement deemed material under SEC Staff Accounting Bulletin No. 99. Reclassified certain redeemable Class A ordinary shares from permanent equity to mezzanine equity, shifting US$ 4.2 million within equity. Recast convertible debenture items under the fair value option; no change to consolidated net loss. Reduced deemed dividend from warrant down-round features to US$ 7.73 million, lifting loss attributable to Sangrix to US$ 16.4 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangrix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-108949), on September 18, 2026, and is solely responsible for the information contained therein. (C) Copyrig